News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
157 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39673)
2015 (44433)
2016 (38330)
2017 (37190)
2018 (39124)
2019 (51338)
2020 (57666)
2021 (58724)
2022 (53929)
2023 (42568)
2024 (38488)
2025 (26402)
Month
January (2488)
February (2603)
March (3228)
April (2950)
May (3962)
June (3500)
July (2854)
August (3142)
September (3205)
October (3540)
November (3386)
December (2332)
Day
1 (247)
2 (234)
3 (123)
4 (6)
5 (2)
6 (157)
7 (294)
8 (215)
9 (227)
10 (147)
11 (6)
12 (2)
13 (213)
14 (201)
15 (161)
16 (149)
17 (68)
19 (2)
20 (132)
21 (113)
22 (70)
23 (4)
24 (6)
26 (9)
27 (154)
28 (186)
29 (127)
30 (131)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Month
January
February
March
April
May
June
July
August
September
October
November
December
Day
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
19
20
21
22
23
24
26
27
28
29
30
Drug Development
Stealth BioTherapeutics Initiates Phase III Study of Elamipretide in Patients with Primary Mitochondrial Myopathy
Pivotal trial to evaluate treatment for disease with no FDA-approved treatment options
November 6, 2017
·
3 min read
BioMidwest
Moleculera Labs Issued Key U.S. Patent Covering the Company’s Diagnostic Panel for Infection-Induced Autoimmune Neuropsychiatric Disorders
Moleculera Labs, today announced that a key patent has issued covering the company’s Cunningham Panel and its use in helping physicians identify whether an individual’s neurologic and/or psychiatric symptoms could be caused by an autoimmune dysfunction.
November 6, 2017
·
2 min read
Business
Anthera Pharmaceuticals Provides Business Update and Reports 2017 Third Quarter Financial Results
November 6, 2017
·
10 min read
Drug Development
The Medicines Company and Alnylam Pharmaceuticals Announce Initiation of Phase III Clinical Trials of Inclisiran
The Medicines Company today announced the initiation of the Phase III clinical program for inclisiran, with the commencement of patient dosing on November 1, 2017 in the ORION-11 trial.
November 6, 2017
·
16 min read
Pharm Country
Artemis Therapeutics Receives Orphan Drug Designation From FDA for Artemisone for the Treatment of Malaria
Artemis is now qualified to receive significant benefits throughout its orphan drug development program including more frequent FDA interactions, protocol assistance, and tax credits for clinical research costs.
November 6, 2017
·
3 min read
Drug Development
Flex Pharma Reports Positive Topline Data From Exploratory Phase II Trial of FLX-787 in ALS
The study was terminated early to focus the Company’s resources on the ongoing US Phase 2b ALS study (COMMEND).
November 6, 2017
·
7 min read
Drug Development
Alpine Immune Sciences Presents ALPN-101 Program Data Demonstrating Potent Preclinical Activity in Arthritis and Inflammation
Findings suggest molecules from the company’s vIgD platform could potentially have clinical therapeutic utility in multiple inflammatory diseases.
November 6, 2017
·
5 min read
Business
Translate Bio Appoints Ann Barbier, M.D., Ph.D., as Chief Medical Officer
Translate Bio today announced the appointment of Ann Barbier, M.D., Ph.D., as chief medical officer, effective immediately.
November 6, 2017
·
2 min read
Drug Development
UroGen Pharma Announces First Patient Enrolled in Allergan Phase II Clinical Trial of RTGel in Combination With BOTOX for the Treatment of Overactive Bladder
The trial is being conducted by Allergan Pharmaceuticals International Limited, or Allergan, a wholly owned subsidiary of Allergan plc, under the terms of a license agreement with UroGen Pharma.
November 6, 2017
·
5 min read
Drug Development
BriaCell Provides Clinical Update on its Lead Vaccine Candidate, BriaVax
The Phase I/IIa study evaluates the safety and activity of BriaVax in patients with advanced breast cancer. To boost the anti-tumor effects of BriaVax.
November 6, 2017
·
6 min read
Previous
4 of 16
Next